- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 6 - Emerging Treatments
Ms Young notes that while there is no cure, there has been tremendous progress in the development of newer drug classes.
Ms Young notes that while there is no cure, there has been tremendous progress in the development of newer drug classes. Patients have had response rates as high as 95% or greater with newer treatments. However, with disease progression and the relapse refractory setting, response rates can drop to 25% to 30%. There are also patients who don’t respond to specific agents, or respond then relapse very quickly.
“It’s really important to try and figure out what type of myeloma a patient may have, and the best way to treat, because there are some very low-risk types of myeloma that can be managed very well with standard therapies and then there are more aggressive types that really do need these newer agents and combinations,” says Ms Young.
Dr Goldberg discusses why a drug’s deliverability—among other factors—is important.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
